PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Shanghai Fosun Pharmaceutical Group Co Ltd (2196.H...
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINCNE100001M79
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Highlights

Market CapHK$59.00B
EPS (TTM)HK$0.78
PE Ratio16.37
PEG Ratio1.00
Total Revenue (TTM)HK$30.16B
Gross Profit (TTM)HK$14.19B
Year RangeHK$11.32 - HK$21.10
Target PriceHK$17.34

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Shanghai Fosun Pharmaceutical Group Co Ltd

Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in Shanghai Fosun Pharmaceutical Group Co Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


50.00%100.00%150.00%200.00%250.00%300.00%FebruaryMarchAprilMayJuneJuly
44.30%
285.18%
2196.HK (Shanghai Fosun Pharmaceutical Group Co Ltd)
Benchmark (^GSPC)

S&P 500

Returns By Period

Shanghai Fosun Pharmaceutical Group Co Ltd had a return of -22.00% year-to-date (YTD) and -34.18% in the last 12 months. Over the past 10 years, Shanghai Fosun Pharmaceutical Group Co Ltd had an annualized return of -5.91%, while the S&P 500 had an annualized return of 10.58%, indicating that Shanghai Fosun Pharmaceutical Group Co Ltd did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-22.00%13.20%
1 month3.11%-1.28%
6 months-8.93%10.32%
1 year-34.18%18.23%
5 years (annualized)-10.44%12.31%
10 years (annualized)-5.91%10.58%

Monthly Returns

The table below presents the monthly returns of 2196.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-22.00%6.79%-9.60%-3.75%-0.65%8.01%-22.82%
20230.80%-8.93%-2.83%0.22%-4.70%-1.88%0.29%-9.95%-0.33%-1.96%-4.21%-1.62%-30.47%
2022-9.17%0.32%22.36%-11.49%-2.51%-10.26%-2.24%-10.74%-24.89%4.10%30.17%-3.10%-25.70%
2021-5.53%4.57%-9.43%48.87%31.00%-3.02%14.44%-29.82%-19.74%-8.36%9.95%-14.87%-6.43%
2020-11.06%5.02%16.17%16.08%-16.89%5.28%43.31%-10.64%-1.83%-0.93%2.35%13.65%59.67%
20193.70%16.77%1.80%-4.94%-14.47%2.60%0.64%-0.64%-9.66%5.46%-0.90%6.82%3.71%
2018-9.37%0.22%5.82%-10.89%17.00%-14.33%-11.96%-15.35%-2.68%-23.83%14.89%-14.81%-53.58%
20179.05%3.09%7.12%2.62%1.70%1.34%-4.11%2.80%10.20%20.22%-3.21%33.02%114.17%
2016-17.60%-2.81%18.76%-1.40%-4.27%-4.56%0.63%18.30%7.11%-1.04%2.31%-2.66%7.67%
20150.54%-8.02%0.19%14.31%13.03%-13.92%-20.00%0.02%7.06%4.12%-0.59%-10.36%-18.09%
20142.14%15.93%-2.35%-2.96%9.92%0.35%-10.90%-0.79%-0.60%11.38%-0.36%0.36%21.12%
2013-0.85%3.27%16.67%-0.14%-2.15%-7.60%9.55%-6.78%6.80%29.93%13.23%17.57%103.44%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of 2196.HK is 11, indicating that it is in the bottom 11% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of 2196.HK is 1111
2196.HK (Shanghai Fosun Pharmaceutical Group Co Ltd)
The Sharpe Ratio Rank of 2196.HK is 44Sharpe Ratio Rank
The Sortino Ratio Rank of 2196.HK is 66Sortino Ratio Rank
The Omega Ratio Rank of 2196.HK is 99Omega Ratio Rank
The Calmar Ratio Rank of 2196.HK is 2424Calmar Ratio Rank
The Martin Ratio Rank of 2196.HK is 1111Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Shanghai Fosun Pharmaceutical Group Co Ltd (2196.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


2196.HK
Sharpe ratio
The chart of Sharpe ratio for 2196.HK, currently valued at -1.04, compared to the broader market-2.00-1.000.001.002.003.00-1.04
Sortino ratio
The chart of Sortino ratio for 2196.HK, currently valued at -1.49, compared to the broader market-4.00-2.000.002.004.00-1.49
Omega ratio
The chart of Omega ratio for 2196.HK, currently valued at 0.83, compared to the broader market0.501.001.502.000.83
Calmar ratio
The chart of Calmar ratio for 2196.HK, currently valued at -0.40, compared to the broader market0.001.002.003.004.005.00-0.40
Martin ratio
The chart of Martin ratio for 2196.HK, currently valued at -1.27, compared to the broader market-30.00-20.00-10.000.0010.0020.00-1.27
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.58, compared to the broader market-2.00-1.000.001.002.003.001.58
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.22, compared to the broader market-4.00-2.000.002.004.002.22
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.28, compared to the broader market0.501.001.502.001.28
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.29, compared to the broader market0.001.002.003.004.005.001.29
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 5.98, compared to the broader market-30.00-20.00-10.000.0010.0020.005.98

Sharpe Ratio

The current Shanghai Fosun Pharmaceutical Group Co Ltd Sharpe ratio is -1.06. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Shanghai Fosun Pharmaceutical Group Co Ltd with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-2.00-1.000.001.002.003.00FebruaryMarchAprilMayJuneJuly
-1.04
1.57
2196.HK (Shanghai Fosun Pharmaceutical Group Co Ltd)
Benchmark (^GSPC)

Dividends

Dividend History

Shanghai Fosun Pharmaceutical Group Co Ltd granted a 5.56% dividend yield in the last twelve months. The annual payout for that period amounted to HK$0.73 per share.


PeriodTTM20232022202120202019201820172016201520142013
DividendHK$0.73HK$0.46HK$0.66HK$0.52HK$0.43HK$0.36HK$0.46HK$0.40HK$0.38HK$0.36HK$0.34HK$0.26

Dividend yield

5.56%2.71%2.64%1.51%1.16%1.53%2.00%0.80%1.59%1.58%1.22%1.11%

Monthly Dividends

The table displays the monthly dividend distributions for Shanghai Fosun Pharmaceutical Group Co Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.27HK$0.27
2023HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.46HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.46
2022HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.66HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.66
2021HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.52HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.52
2020HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.43HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.43
2019HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.36HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.36
2018HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.46HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.46
2017HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.40HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.40
2016HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.38HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.38
2015HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.36HK$0.00HK$0.00HK$0.00HK$0.00HK$0.36
2014HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.34HK$0.00HK$0.00HK$0.00HK$0.00HK$0.34
2013HK$0.26HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.26

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%3.5%
Shanghai Fosun Pharmaceutical Group Co Ltd has a dividend yield of 3.47%, which is quite average when compared to the overall market.
Payout Ratio
20.0%40.0%60.0%80.0%100.0%120.0%93.6%
Shanghai Fosun Pharmaceutical Group Co Ltd has a payout ratio of 93.59%, which is above the market average. This might signify the company's strong earnings or financial health. However, it could also hint at a more mature business phase with potentially slower growth.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%FebruaryMarchAprilMayJuneJuly
-82.21%
-4.74%
2196.HK (Shanghai Fosun Pharmaceutical Group Co Ltd)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Shanghai Fosun Pharmaceutical Group Co Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Shanghai Fosun Pharmaceutical Group Co Ltd was 84.57%, occurring on Apr 16, 2024. The portfolio has not yet recovered.

The current Shanghai Fosun Pharmaceutical Group Co Ltd drawdown is 82.02%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-84.57%Aug 5, 2021663Apr 16, 2024
-62.8%Mar 21, 2018489Mar 16, 2020278May 3, 2021767
-50.19%Jun 1, 2015162Jan 21, 2016338Jun 8, 2017500
-21.94%Jan 15, 201820Feb 9, 201825Mar 20, 201845
-19.74%Mar 12, 201426Apr 16, 2014247Apr 21, 2015273

Volatility

Volatility Chart

The current Shanghai Fosun Pharmaceutical Group Co Ltd volatility is 8.00%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%FebruaryMarchAprilMayJuneJuly
8.00%
3.81%
2196.HK (Shanghai Fosun Pharmaceutical Group Co Ltd)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Shanghai Fosun Pharmaceutical Group Co Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

P/E Ratio

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Shanghai Fosun Pharmaceutical Group Co Ltd.


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items